



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John P. Devlin

S.N. 10/ 773,903

Filed: February 6, 2004

Entitled: DERIVATIVES OF PENTACYCLIC NORTRITERPENE QUINONE  
METHIDES AS COMPOUNDS USEFUL IN THE TREATMENT OF  
INFLAMMATORY, NEURODEGENERATIVE AND NEOPLASTIC  
DISEASES.

Confirmation Number: 8342

Mail Stop: Missing Parts  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RESPONSE

Dear Sir:

In response to the Notice to File Corrected Application Papers, which notice was mailed May 5<sup>th</sup>, 2004, enclosed please find a substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3) and 1.125. A copy of the Notice to File Corrected Application Papers is also included. Additionally, an abstract of the disclosure is enclosed.

Applicant, through his attorney, hereby states that the enclosed substitute specification does not encompass any new matter, but is simply the application as filed on February 6<sup>th</sup>, 2004, in the format dictated by 37 CFR.

Respectfully submitted by

.....  
Mary-Ellen M. Devlin

Reg. No. 27,928

June 30<sup>th</sup>, 2004

Enclosures

275 Wewaka Brook Road  
Bridgewater, CT 06752  
Tel: 860-354-8485